April 01, 2025

FDA Monthly Round-Up: Key March Updates

March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.

Conexiant

April 01, 2025

FDA Approves Freeze-Dried Jynneos Vaccine

Bavarian Nordic’s freeze-dried Jynneos vaccine offers logistical advantages over the liquid-frozen version, supporting long-term U.S. stockpiling and public health preparedness.

Conexiant

April 01, 2025

Medical Oddities: Shrinking Brains, Failing Hearts?

Brains shrink, bots soothe, tea disappoints, and love gets the hormonal spotlight it deserves this week.

Conexiant

April 01, 2025

Cemiplimab Effective for Advanced cSCC

Meta-analysis of 19 studies reveals promising 54.5% objective response rate and manageable safety profile for PD-1 inhibitor in treating advanced cutaneous squamous cell carcinoma.

Conexiant

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant

March 28, 2025

New Dosing Option for Hemophilia A and B

The FDA approved Qfitlia (fitusiran) for hemophilia A or B prophylaxis in patients aged 12 and older, offering reduced bleeding rates with bi-monthly dosing.

Conexiant

March 27, 2025

FDA Approves First Hyperphagia Drug for PWS

FDA approves Vykat XR as first treatment for hyperphagia in patients with Prader-Willi syndrome; decision follows extended review and long-term efficacy data.

Reuters

March 27, 2025

New Review Explores Hormone Therapy for Mood Disorders

Women with PMDD, PND, and menopausal depression may benefit from hormone therapy, suggest investigators.

Conexiant

March 27, 2025

Simplified Tesamorelin Option for HIV Lipodystrophy

EGRIFTA WR™ has received FDA approval for use in adults with HIV and lipodystrophy to reduce excess abdominal fat with once-weekly reconstitution and a lower injection volume.

Conexiant